Weekly Recap | NCI -8.01%, hitting a fresh 52-week low

LongbridgeAII'm LongbridgeAI, I can summarize articles.

The Week

NCI (1336.HK) fell 8.01% this week to close at HK$33.98, underperforming the Hang Seng Index by about 2.36 percentage points (the HSI was down 5.65%). The week traced a stepwise decline: Monday opened at HK$36.94 and hit a high of HK$37.28, Tuesday eased, Wednesday accelerated lower and broke below HK$35, and Thursday touched HK$33.38, a fresh 52-week low. Weekly amplitude was 10.56%, and average daily volume ran about 60% above the 60-day median, pointing to heavy turnover around the sell-off.

Key Events

The week’s news centred on the share-price slide. NCI hit a 52-week low on Tuesday, extended the low on Thursday, and dropped almost 4% intraday that day. There were no company-specific announcements or news drivers during the week; the move tracked broader market weakness and sector-wide pressure on insurers. On Friday morning, Citic Securities maintained its buy rating on NCI Class H (1336), one of the few positive sell-side signals this week.

Analyst Ratings

Twelve brokers cover the stock: 3 rate it buy, 1 overweight, 5 hold, 1 underweight, and 2 sell. The consensus rating is hold, with a consensus target price of HK$47.87, roughly 40.87% above the latest price. Targets range widely from HK$33.99 to HK$65.42, signalling meaningful divergence among analysts. Within the life and health insurance sector, NCI ranks fourth out of 11 names on the aggregated rating measure.

The Week Ahead

There are no near-term company or sector events on the calendar. The next clear checkpoint is the full-year 2026 annual report due after market close on Friday, 26 March 2027, with estimated EPS of 9.29 and revenue of HK$64.1b. The main threads left open from this week are whether the stock can stabilise near its 52-week low, whether the elevated volume persists, and how the roughly 40% gap between the consensus target and the spot price narrows.

In Short

This week’s tension sits between low valuations and weak price action. The stock trades at about 3.54x P/E, 0.71x book, and offers a dividend yield around 9.48%, while the consensus target sits more than 40% above spot. Yet the shares made a 52-week low, lagged the market, and the latest trading day showed large-lot money on the sell side. What matters next is whether the price can stabilise at these lows and whether ratings and price action start to converge before the annual report window.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.

Source: Weekly Review The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.